World Arthritis Day: Europe needs science-based weight loss programmes to tackle the rising burden of osteoarthritis

TDMR Europe welcomes World Arthritis Day (WAD) 2024. Taking place annually on 12th October, WAD is a global awareness day aimed towards increasing knowledge of the existence and impact of rheumatic and musculoskeletal diseases (RMDs) among all relevant audiences. This year, WOD is focused on helping people living with RMDs make evidence-informed choices in partnership with their healthcare professionals to improve their overall health and quality of life. In this context, TDMR Europe stresses the need to raise awareness of the role of weight loss in tackling osteoarthritis in people with obesity or overweight.

The role of weight loss in improving osteoarthritis in people with obesity

According to the National Institute for Health and Excellence (NICE), osteoarthritis is more common in people with obesity, among other risk groups. The NICE Guidance “Osteoarthritis in over 16s: diagnosis and management” argues that weight loss can help improve the quality of life and physical function and reduce pain in people with osteoarthritis and obesity. The Guidance also claims that “losing 10% of their body weight is likely to be better than 5%”.

Research shows the effectiveness of low and very-low energy diet

In a recent webinar organised by TDMR Europe, Professor Henning Bliddal, Director of the Parker Institute, a clinical research unit of rheumatology at Frederiksberg University Hospital, Copenhagen, demonstrated that weight loss with total diet replacement (TDR) and meal replacement products (MRPs) can help people with obesity and knee osteoarthritis lose weight and improve their health.

Prof Bliddal presented the results of the CAROT study, a two-year trial that enrolled 192 patients with obesity and knee osteoarthritis. The trial had two phases, the first (16 weeks) consisting of a dietary intervention with low-energy diet (LED) and the second (52 weeks) a randomized, three group controlled study of maintenance of weight loss by either continuing dietary instruction (and use of one meal replacement product daily), exercise, or a control group.

Prof Bliddal showed that at the end of the first phase “two out of three participants had very significant pain relief and better function”.  According to Prof Bliddal, “with a 16-week programme you can make people a lot better in, should we say, no time, in a simple way”.

A three-year follow up study divided participants into two groups, providing either an “ordinary” diet combined with one MRP per day or reintroduction of five weeks of TDR every four months (nine episodes of 5 weeks TDR over 3 years). Prof Bliddal explained that during this trial, the rate of knee replacement was lower than expected and while patients were reluctant to exercise, they managed to maintain their weight loss over those three years.

In order to take the Danish evidence a step further and apply it to the United Kingdom, Versus Arthritis the UK’s largest arthritis charity funded a feasibility trial of a package of care for people awaiting knee surgery, led by Professor Hamish Simpson at the University of Edinburgh.  Published in February 2024 this study showed that a package of care including weight loss giving an average 11.2kg weight loss with TDR (10.4% compared to 1.2% in the control group) was feasible.  Symptoms, including pain, stiffness and physical function improved more in the intervention than the control group. Ten percent of intervention participants cancelled their surgery because symptoms were so improved.  Adherence to interventions was 100% except for exercise therapy and the overall positive effect on participants’ quality of life suggests that this combination of weight loss with TDR, exercise therapy, use of insoles, and analgesia optimisation, should be offered to the many thousands of people in the UK languishing with pain and social isolation due to immobility while they await knee surgery.

Three months later another study exploring the role of low-energy diet (LED) in addressing obesity and knee osteoarthritis was published. The POWER randomised control trial, published in the British Journal of Sports Medicine, examined the effectiveness of a physiotherapist-delivered intensive diet programme for knee osteoarthritis, run in Melbourne, Australia.

The POWER trial is the first study to show that a physiotherapist-delivered 800kcal/d LED incorporating two MRPs daily and an exercise program is safe and effective for weight loss compared to exercise alone in people with obesity and knee osteoarthritis. Participants lost 8.1% body weight over six months (compared to just 1% in control participants).. As the researchers have stressed, “this study provides the first proof-of-concept evidence of an alternate allied health clinician delivery model for weight loss in people with knee osteoarthritis, which may guide future research and policy in the face of rising obesity rates and challenges facing healthcare systems”.

The rising burden of osteoarthritis

Osteoarthritis affects millions in Europe, with the Economist Intelligence Unit estimating that the number of people affected in Western Europe was 57 million in 2019, growing by 54% over the past 30 years.

European countries have reported annual osteoarthritis-related costs in the billions of Euros, with direct and indirect healthcare costs reaching 7.2 and 4.6 billion Euros respectively (Economist Intelligence Unit)

In addition to these substantial healthcare costs, osteoarthritis also impacts Europe’s economy by causing absenteeism and early retirement, necessitating income support or disability allowance payments. Some people with osteoarthritis may also need some degree of nursing and social care.

In the light of these findings, it is urgent for governments across Europe to take note of the research showing the effectiveness of weight loss in tackling osteoarthritis in people with obesity and introduce science-based measures in the public health sector, including TDR and MRP diet programmes.

TDMR Europe works to help stakeholders develop a better understanding of formula diet foods and aims to increase awareness of the scientific evidence showing the effectiveness of these products in tackling obesity and improving related comorbidities. Find out more here

Footnotes:

Total Diet Replacements (TDRs) which include very low calorie diets (VLEDs) and low calorie diets (LEDs), are specifically formulated programmes that are based around formula foods that aim to replace the whole of the daily diet. These formula foods are nutritionally balanced with key vitamins, minerals, high quality protein, essential fats, fibre and other nutrients, and are designed to replace conventional foods for a period to facilitate optimal weight loss. They provide controlled energy intake lower than can be achieved with a reduced intake of normal foods.

Meal replacements (MRPs) are products presented as a replacement for one or two meals of the daily diet. They are used alongside conventional food, as part of an energy restricted diet, to facilitate and maintain weight loss. MRPs are low-calorie meals taken in place of breakfast, lunch or dinner. They contain between 200kcal and 250kcal and come in pre-rationed form. This makes it easier for people who are looking to lose or maintain weight to control their calorie intake, as they no longer need to control their portions like they would need to do with ‘normal foods’.

Aris Myriskos

TDMR Europe Secretariat

EU needs obesity management policy as the condition hits record high

Press release

10 October 2024

Sixty percent of Europeans living with overweight and obesity are being let down by the European Commission’s strategy to tackle the condition at a cost of €70 billion per year.

According to a WHO analysis obesity and overweight affect almost 60% of adults across Europe and is the cause of at least 200,000 new cancer cases annually as well as acting as gateway to cardiovascular disease and type 2 diabetes (T2DM). Research shows that associated healthcare costs and reductions in productivity are costing EU Member States €70 billion per year.

TDMR Europe has published a manifesto for the EU’s term 2024 – 2029. The initiative highlights that Europe’s Beating Cancer Plan, EU4Health and the Farm to Fork (F2F) Strategy have primarily focussed on obesity prevention through healthy eating and exercise. TDMR Europe argues that there is no or little consideration of those who already have obesity or overweight and who are struggling to manage their weight and related problems.

While recognising that responsibility for delivery of health care is devolved to national governments, TDMR Europe is calling for the strategy to be rebalanced to include recommendations to utilise all clinically proven options for weight reduction and maintenance programmes including total diet and meal replacement products.

The Group highlights the vast amount of scientific evidence showing the effectiveness of the products, such as the EU funded ‘PREVIEW’ trial, a three-year study conducted on people with obesity and pre-diabetes in Europe and around the world. The study showed that an average of 10% weight loss with total diet replacement (TDR) followed by a low glycaemic index (GI) diet provided better weight loss maintenance than other diets and reduced the development of diabetes to below the expected level.

The manifesto also cites examples outside research settings, such as the English National Health Service (NHS) TDR programme where 27% of 710 participants with T2DM went into remission with an average weight loss of 14.8kg. Patient groups have said that the programme was easy to incorporate into their lives. In addition to weight loss and improved blood glucose levels, they had increased energy, mobility, and functional fitness, and self-esteem improved. Participants said that the diet replacement programme and products gave them a sense of control over their energy consumption that they struggled to manage with their usual conventional-food diet.

Professor Anthony Leeds, Chair of TDMR Europe, said:

“EU leaders now have a wonderful opportunity to lead national governments towards a comprehensive solution for the threat of obesity-related conditions and the suffering and high health care costs that they will cause.  Low-cost, safe, scientifically proven options to facilitate weight loss in the 60% of EU citizens who need to weigh less should be recommended. A comprehensive programme must include TDR programmes because these are proven to deliver diabetes remission and are recommended by Europe’s expert panel (the EASD).” 

“Preventive public health programmes to combat obesity must remain in place, must be rigorously evaluated and then effectively delivered, while those who have already become overweight and obese need safe, scientifically proven and cost-effective interventions.”

 

-Ends-

For more information contact aristeidis.myriskos@whitehousecomms.com

Notes to editors

The TDMR Manifesto calls for:

  • Support for a more ambitious role for the EU in public health matters and continue to recognise the complexity of obesity, while ensuring a clear focus on weight management alongside prevention.
  • Issue an EU level action plan on obesity management that explores all scientifically proven weight management methods available, including the use of total diet replacements (TDRs) and meal replacement products (MRPs) for weight control.
  • Ensure a regulatory environment for TDRs and MRPs that is aligned with the latest scientific evidence.
  • Revise the current prohibition on the use of nutrition and health claims for TDRs.

About total diet and meal replacement products

Total diet replacements (TDRs) are diets composed of formula foods and replace the whole of the conventional food intake for a period of weeks to achieve optimal weight loss. Formula foods are nutritionally balanced with key vitamins, minerals, high quality protein, essential fats, and fibre, but with reduced dietary energy content. They provide controlled energy intake lower than can be achieved with a reduced intake of normal foods and have been shown to deliver sufficient weight loss to help people with type 2 diabetes go into remission and improve symptoms and health status in other obesity comorbidities such as cardiovascular disease, osteoarthritis and obstructive sleep apnoea.

Meal replacement products (MRPs) are presented as a replacement for one or two meals of the daily diet. They are used alongside conventional food, as part of an energy restricted diet, to facilitate and maintain weight loss.

About EASD’s recommendation:

Evidence-based European recommendations for the dietary management of diabetes
The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD)
Diabetologia. 2023 Jun;66(6):965-985. doi: 10.1007/s00125-023-05894-8.